Drug-eluting stents biodegradable polymer

Keywords Sirolimus, cyclosporine, tacrolimus, mycophenolic add, drug-eluting stent, durable polymer, biodegradable polymer, bioresorbable polymer, polymeric micelle, nanoparticle... 

Incorporation of tacrolimus on cardiac drug-eluting stent platforms has not performed as favorably to other drugs. Tacrolimus suppresses smooth muscle and endothelial cell proliferation but is less potent than sirolimus. Unlike sirolimus though, taaolimus does not affect tissue factor and endothelial nitric oxide synthase expression. The Mahoroba DBS applies tacrolimus to a cobalt chromium platform with a PLGA biodegradable polymer. The first-in-man results unfortunately demonstrated failure to prevent neointimal hyperplasia, with a cumulative major adverse cardiac events rate of 23.4% at 6 months [7,8]. 

A. Abizaid, and J.R. Costa Jr, New drug-eluting stents An overview on biodegradable and polymer-free next-generation stent systems, Circ. Cardiovasc. Interv, 3 (4), 384-393,2010. 

J.S.W. Kwong, and C.-M. Yu, Clinical outcomes of biodegradable polymer drug-eluting stents for percutaneous coronary intervention An updated meta-analysis of randomized controlled trials, Clin. Cardiol, 37 (7), 440-453,2014. 

---